Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Duchenne muscular dystrophy: Drug development and regulatory considerations.

Muscle & nerve - 1 Jun 2010

McNeil D Elizabeth, Davis Carole, Jillapalli Devanand, Targum Shari, Durmowicz Anthony, Coté Timothy R

Abstract excerpt

Duchenne muscular dystrophy (DMD) is one of the most commonly recognized dystrophinopathies. There are no approved therapeutic options available for this disease but recent discoveries have led to hope that effective therapies might be forthcoming. With funding from patient advocacy groups, private investors, and governmental bodies such as the Food and Drug Administration Office of Orphan Product Development...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgens
Share to Clinical Trials as Topic
Share to Drug Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gentamicins

Share to Muscular Dystrophy, Duchenne

Share to Rare Diseases

Share to Steroids

Share to United States Food and Drug Administration

Source

Identifiers

PMID: 20373504
DOI: 10.1002/mus.21623

Genes

DMD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Duchenne muscular dystrophy: Drug development and regulatory considerations.PMID 20373504Read ↗

Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular DystrophySemantic proximity Read ↗

Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.Semantic proximity Read ↗

New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeutics.Semantic proximity Read ↗

[Duchenne muscular dystrophy: current aspects and perspectives on treatment].Semantic proximity Read ↗

Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging PharmacotherapiesSemantic proximity Read ↗

Pharmacologic Management of Duchenne Muscular Dystrophy: Target Identification and Preclinical TrialsSemantic proximity Read ↗

Drug development progress in duchenne muscular dystrophySemantic proximity Read ↗

Towards a Cure: Emerging Therapeutic Advances for DMD, LGMD, and GNEM- Insights from Pre-Clinical and Clinical ResearchSemantic proximity Read ↗

An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an update.Semantic proximity Read ↗

Interventions for muscular dystrophy: molecular medicines entering the clinic.Semantic proximity Read ↗

Emerging drugs for Duchenne muscular dystrophySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.